Platinum Investment Management Ltd. purchased a new position in shares of Zai Lab (NASDAQ:ZLAB) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 20,000 shares of the company’s stock, valued at approximately $424,000.
Other institutional investors have also bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of Zai Lab by 64.9% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 917,123 shares of the company’s stock worth $19,471,000 after acquiring an additional 360,801 shares during the period. Segantii Capital Management Ltd raised its position in shares of Zai Lab by 68.7% in the fourth quarter. Segantii Capital Management Ltd now owns 382,769 shares of the company’s stock valued at $8,126,000 after buying an additional 155,912 shares in the last quarter. Hudson Bay Capital Management LP raised its position in shares of Zai Lab by 71.7% in the fourth quarter. Hudson Bay Capital Management LP now owns 164,574 shares of the company’s stock valued at $3,494,000 after buying an additional 68,729 shares in the last quarter. NINE MASTS CAPITAL Ltd raised its position in shares of Zai Lab by 28.0% in the fourth quarter. NINE MASTS CAPITAL Ltd now owns 64,000 shares of the company’s stock valued at $1,359,000 after buying an additional 14,000 shares in the last quarter. Finally, Pinebridge Investments L.P. acquired a new stake in shares of Zai Lab in the third quarter valued at approximately $945,000. Institutional investors and hedge funds own 21.00% of the company’s stock.
A number of equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a research report on Thursday, March 22nd. Leerink Swann reiterated an “outperform” rating on shares of Zai Lab in a research report on Friday, March 23rd. Finally, JPMorgan Chase upgraded shares of Zai Lab from a “neutral” rating to an “overweight” rating and set a $32.00 price target for the company in a research report on Wednesday, February 14th.
Shares of ZLAB opened at $21.44 on Friday. Zai Lab has a one year low of $19.80 and a one year high of $35.74.
WARNING: “20,000 Shares in Zai Lab (NASDAQ:ZLAB) Acquired by Platinum Investment Management Ltd.” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/platinum-investment-management-ltd-acquires-new-position-in-zai-lab-ltd-zlab.html.
Zai Lab Company Profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.